AbCellera Biologics (ABCL) PT Lowered to $38 at Berenberg
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ABCL Hot Sheet
Price: $12.20 +0.16%
Rating Summary:
14 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
14 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Berenberg analyst Gaurav Goparaju lowered the price target on AbCellera Biologics (NASDAQ: ABCL) to $38.00 (from $43.00) while maintaining a Buy rating.
You May Also Be Interested In
- Matador (MTDR) PT Raised to $66 at Truist Securities
- Zimmer Biomet (ZBH) PT Raised to $120 at Jefferies
- Marriott International (MAR) PT Lowered to $141 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
